The Quantellect read.As of Nov 19, 2026, 9 active firms cover Aveanna Healthcare Holdings Inc: 6 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $11.00 to $16.00, a moderate spread. The average target of $14.25 sits 31% above the current $10.84. The rating mix has stayed broadly stable, with Buy-side ratings easing from 7 to 6 over recent months. On the fundamentals, the Street sees revenue growth near 5% this year and 6% next, consensus EPS building from about $0.21 next quarter toward $0.91 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 active firms
Buy
Strong Buy111%
Buy556%
Neutral333%
Sell00%
Strong Sell00%
Based on 9 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$14.25
+31.5% upside
Average target across 8 active firms as of Nov 19, 2026 vs $10.84 current
Highest Target$16.00
Average Target$14.25
Lowest Target$11.00
Detailed analyst forecasts for AVAH
Showing 1–9 of 9 named analysts shown · 9 active firms in the rating projection
As of Nov 19, 2026, 6 of 9 active firms rate AVAH a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
AVAH EPS & revenue forecast
EPS · NEXT QUARTER
$0.21
Range $0.17 – $0.22 · 6 analysts · +17% YoY
Next period, 6 analysts expect Aveanna Healthcare Holdings Inc to earn $0.21 a share (range $0.17 – $0.22), versus $0.18 a year earlier. Full-year consensus is $0.84, growing to $0.91 the year after.
REVENUE · NEXT QUARTER
$714.5M
Range $697.5M – $725.0M · 6 analysts · +6% YoY
Revenue is expected to reach $714.5M (range $697.5M – $725.0M), +6.0% year-over-year. Full-year consensus is $2.7B, rising to $2.9B next year.
Top analysts covering Aveanna Healthcare Holdings Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AVAH.
#1
DM
David Macdonald
Truist Securities · Rank #111
Neutral
$15.00+38.4% to target
Overall win rate
50%
+ Follow
#2
Ben Hendrix
RBC Capital · Rank #150
Buy
$16.00+47.6% to target
Overall win rate
44%
+ Follow
#3
Brian Tanquilut
Jefferies · Rank #280
Buy
$10.00-7.7% to target
Overall win rate
46%
+ Follow
#4
AR
A.J. Rice
UBS · Rank #365
Neutral
$13.00+19.9% to target
Overall win rate
35%
+ Follow
#5
Andrew Mok
Barclays · Rank #385
Buy
$15.00+38.4% to target
Overall win rate
39%
+ Follow
AVAH stock forecast FAQ
What is AVAH's average 12-month price target?+
The 8 active firms with a live target average $14.25 for Aveanna Healthcare Holdings Inc over the next 12 months, ranging from a $16.00 high to a $11.00 low, as of Nov 19, 2026.
Is AVAH stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 9 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for AVAH?+
The Street-high target is $16.00 (RBC Capital), and the Street-low is $11.00 (Stephens & Co.). The average of all 8 active-firm targets is $14.25.
How many active Wall Street firms cover AVAH?+
9 active firms have a recognized rating on Aveanna Healthcare Holdings Inc as of Nov 19, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering AVAH?+
Among analysts who currently cover AVAH, David Macdonald of Truist Securities has the strongest overall Quantellect track record (Rank #111). Their current call is Neutral with a $15.00 target.
What is Aveanna Healthcare Holdings Inc's projected EPS for next quarter?+
The consensus estimate is $0.21 per share (range $0.17 – $0.22) across 6 analysts. Full-year EPS is projected at $0.84, rising to $0.91 the following year.
How much revenue is Aveanna Healthcare Holdings Inc expected to report next quarter?+
Consensus revenue is $714.5M (range $697.5M – $725.0M). Full-year revenue is projected at $2.7B, growing to $2.9B next year.
Have analysts been upgrading or downgrading AVAH lately?+
As of Nov 19, 2026, 6 of 9 active firms rate AVAH a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AVAH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.